References concerning
23-valent Pneumococcal Polysaccharide Vaccine

The references are organized chronologically under each subheading

Epidemiology of pneumococcal disease

Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO; **the U.S. Pediatric Multicenter Pneumococcal Surveillance Group.** Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J 2006 Apr; 25(4):301-5.

Hanna JN, Humphreys JL, Murphy DM. Invasive pneumococcal disease in Indigenous people in north Queensland, 1999-2004. Med J Aust 2006 Feb 6;184(3):118-21.

Melegaro A, Edmunds WJ, Pebody R, Miller E, George R. The current burden of pneumococcal disease in England and Wales. J Infect 2006 Jan; 52(1):37-48.

Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006 Jan 23; 24(4): 468-75.

Adegbola RA, Hill PC, Secka O, Ikumapayi UN, Lahai G, Greenwood BM, Corrah T. Serotype and antimicrobial susceptibility patterns of isolates of Streptococcus pneumoniae causing invasive disease in The Gambia 1996-2003. Trop Med Int Health 2006 Jul; 11(7): 1128-35.

Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. Invasive pneumococcal disease in central Australia. Med J Aust. 1995 Feb 20;162(4):182-6.

Chambers S, Laing R, Murdoch D, Frampton C, Jennings L, Karalus N, Mills G, Town I. Māori have a much higher incidence of community-acquired pneumonia and pneumococcal pneumonia than non-Māori: findings from two New Zealand hospitals. N Z Med J 2006 May 19;119(1234):U1978.

Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG. Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005 Oct 26;294(16):2043-51.

Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005 Sep 16;54(36):893-7.

Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005 Mar 26-Apr 1; 365(9465):1147-52.

Kyaw MH, Clarke S, Edwards GF, Jones IG, and Campbell H. Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies. Epidemiol Infect 2000. 125(3): p. 561-72.

von Kries R, Siedler A, Schmitt HJ, et al. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis 2000; 31: 482–7.

Rohani, MY, Raudzah A, Ng AJ, Ng PP, Zaidatul AA, Asmah I, Murtaza M, Parasakthy N, Mohd Yasmin MY, and Cheong YM. Epidemiology of Streptococcus pneumoniae infection in Malaysia. Epidemiol Infect 1999; 122(1): p. 77-82.

Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. Invasive pneumococcal disease in central Australia. Med J Aust 1995 Feb 20; 162(4):182-6.

Reviews of pneumococcal vaccine efficacy/effectiveness including meta-analyses

Scott P, Egger M, Huss A. Effectiveness of pneumococcal polysaccharide vaccine: systematic review and meta-analysis of randomised controlled trials. In press, CMAJ Oct 17, 2008.

Moberley S, Holden J, Tatham D, Andrews R. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008 Jan 23;(1):CD000422.

Chang CC, Singleton RJ, Morris PS, and Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2007(2): p. CD006316.

Jacobson RM, Targonski PV, Poland GA. Why is evidence-based medicine so harsh on vaccines? An exploration of the method and its natural biases. Vaccine 2007; 25:3165-9.

De Vito C, Manzoli L, Marzuillo C, Anastasi D, Boccia A, Villari P. A systematic review evaluating the potential for bias and the methodological quality of meta-analyses in vaccinology. Vaccine 2007;25:8794-806.

Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19(4): p. 353-63.

Fedson DS, Liss C. Precise answers to the wrong question: Prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004;22:927-46.

Conaty S, Watson L, Dinnes J, and Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22(23-24): p. 3214-24.

Straetemans M, Sanders EA, Veenhoven RH, Schilder AG, Damoiseaux RA, Zielhuis GA. Pneumococcal vaccines for preventing otitis media. Cochrane Database Syst Rev 2004(1): p. CD001480.

Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003(4): p. CD000422.

Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003 Feb;3(2):71-8.

Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348(18):1747-55.

Puig-Barbera J, Belenguer Varea A. Goterris Pinto M. Brines Benlliure MJ. [Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis]. Aten Primaria 2002; 30(5): p. 269-81; discussion 281-3.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): p. 1539-58.

Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20(17-18): p. 2166-73.

Cornu C, Yzèbe D, Léophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001 Sep 14;19(32):4780-90.

Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1: p. 1.

Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine: Meta-analysis. Can Fam Physician 1999; 45: 2381-93.

Jacobson RM. Promises and pitfalls of meta-analysis in vaccine research. Vaccine 1999;17:1628-34.

Go ES, Ballas ZK.. Anti-pneumococcal antibody response in normal subjects: a meta-analysis. J Allergy Clin Immunol 1996; 98(1): p. 205-15.

Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN. Efficacy of pneumococcal vaccination in adults: A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.

Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991 Nov 21;325(21):1453-60.

Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. Jama 1977; 238(24): p. 2613-6.

Individual PV23 studies

Singleton RJ, Butler JC, Bulkow LR, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 2007; 25:2288-95.

Johnstone J, Marrie TJ, Eurich DT, Madjumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167(18):1938-1943.

Manoff S, Liss C, Caulfield MJ, Boslego J, Romero-Steiner S, Rajam G, Glass N, Whitney CG, Carlone GM, and the Pneumococcal Revaccination Study Group. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults ≥65 years of age. Presented at the 12th International Congress on Infectious Diseases, Lisbon, Portugal, June 2006.

Mykietiuk A, Carratalà J, Domínguez A, Manzur A, Fernández-Sabé N, Dorca J, Tubau F, Manresa F, Gudiol F. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006 Jul;25(7):457

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C; EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006 Oct 1;43(7):860-8.

Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, Cates CJ, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006(4): p. CD001390.

Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, Merino M, Perez J, Lima J. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61(3): p. 189-95.

Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease--the effect of ongoing, systemic steroid treatment. Vaccine 2006; 24(9): p. 1408-12.

Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J. Prior pneumoccoccal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42:1093-1101

Ansaldi F, Turello V, Lai P, Bastone G, De Luca S, Rosselli R, Durando P, Sticchi L, Gasparini R, Delfino E, Icardi G. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res 2005 Sep-Oct; 33(5):490-500.

Dominguez A, Salleras L, Fedson D, Izquierdo C, Ruiz L, Ciruela P, et al.Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case control study. Clinical Infectious Diseases 2005;40:1250–7.

Lipsky BA, Hirschmann JV. Pneumococcal polysaccharide vaccines do not protect the elderly from pneumococcal infections. Neth J Med 2004; 62(2): p. 33-5.

Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev 2004(1): p. CD003885.

Zhogolev SD, Ogarkov PI, Mel'nichenko PI. [The prophylaxis of nonhospital pneumonia using 23-valent pneumococcus vaccine in the military collectives] Voen Med Zh. 2004 Dec; 325(12):35-43, 96.

Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003 May 1; 348(18):1747-55.

Crum NF, Wallace MR, Lamb CR, Conlin AM, Amundson DE, Olson PE, Ryan MA, Robinson TJ, Gray GC, Earhart KC. Halting a pneumococcal pneumonia outbreak among United States Marine Corps trainees. Am J Prev Med 2003 Aug; 25(2):107-11.

Benin AL, O'Brien KL, Watt JP, et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J Infect Dis 188:81-89, 2003.

Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. Cochrane Database Syst Rev, 2002(1): p. CD002165.

Fry AM, Zell ER, Schuchat A, et al. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 21:303-311, 2002.

Örtqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelof B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351(9100): p. 399-403.

Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103(4): p. 281-90.

Lehmann D, Marshall TF, Riley ID, Alpers MP. Effect of pneumococcal vaccine on morbidity from acute lower respiratory tract infections in Papua New Guinean children. Ann Trop Paediatr 1991; 11(3): p. 247-57.

Sims R, Steinmann W, McConville M, King L, Zwick W, Schwartz S. The clinical effectiveness of pneumococcal vaccine in the elderly. Annals of Internal Medicine 1988;108(5):653–7.

Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987; 136(4): p. 361-5.

Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 1987; 92(2): p. 204-12.

Douglas, RM, Hansman D, McDonald B, Paton J, Kirke K. Pneumococcal vaccine in aboriginal children--a randomized controlled trial involving 60 children. Community Health Stud 1986; 10(2): p. 189-96.
Riley ID, Lehmann D, Alpers MP, Marshall TF, Gratten H, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986; 2(8512): p. 877-81.

Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, Richmond AS, Smith RP, Schiffman G, Shepard DS, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315(21): p. 1318-27.

Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma. Eur J Cancer Clin Oncol, 1986. 22(7): p. 807-13.

Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Bru JP, Stahl JP, Delormas P, Micoud M. [Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions]. Rev Epidemiol Sante Publique 1985; 33(6): p. 437-44.

Rosen C, Christensen P, Henrichsen J, Hovelius B, Prellner K. Beneficial effect of pneumococcal vaccination on otitis media in children over two years old. Int J Pediatr Otorhinolaryngol 1984; 7(3): p. 239-46.

Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis 1984; 149(6): p. 861-9.

John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed) 1984; 288(6430): p. 1567-70.

Shapiro E, Clemens J. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Annals of Internal Medicine 1984;101(3): 325–30.

Lawrence EM, Edwards KM, Schiffman G, et al. Pneumococcal vaccine in normal children. Primary and secondary vaccination. Am J Dis Child 1983; 137:846-850.

Karsh J, Pavlidis N, Schiffman G, Moutsopoulos HM. Immunization of patients with Sjogren's syndrome with pneumococcal polysaccharide vaccine: a randomized trial. Arthritis Rheum 1980; 23(11): p. 1294-8.

Riley ID, Tarr PI, Andrews M, Pfeiffer M, Howard R, Challands P, Jennison G. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977 Jun 25; 1(8026):1338-41.

Kaufman P. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide; results of a six year study. Arch Intern Med, 1947. 79: p. 518.

PPV23 and HIV

Veras MA, Enanoria WT, Castilho EA, Reingold AL. Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study. BMC Infect Dis. 2007 Oct 23;7:119.

Peñaranda M, Falco V, Payeras A, Jordano Q, Curran A, Pareja A, Samperiz G, Dalmau D, Ribera E, Riera M. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: A case-control study. Clin Infect Dis 2007 Oct 1;45:e82-7.

Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Li J, Campsmith M, Whitney CG, Schuchat A. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization.Ann Intern Med 2006 Jan 3;144(1):1-9.

Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS. 2006 Feb 14;20(3):437-44.

Miiro G, Kayhty H, Watera C, Tolmie H, Whitworth JA, Gilks CF, French N. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005 Nov 15; 192(10):1801-5.

Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F; Spanish Pneumococcal Infection Study Network 03/103).Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med. 2005 Jul 11;165(13):1533-40.

Ranieri R, Veronelli A, Santambrogio C, Pontiroli AE. Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. AIDS Res Hum Retroviruses 2005 May; 21(5):407-9.

Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine. 2004 May 7;22(15-16):2006-12.

Watera C, Nakiyingi J, Miiro G, Muwonge R, Whitworth JA, Gilks CF, French N. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004 May 21;18(8):1210-3.

Tasker SA, Wallace MR, Rubins JB, Paxton WB, O'Brien J, Janoff EN. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002 Mar 15; 34(6):813-21.

Pierce AB, Hoy JF. Is the recommendation for pneumococcal vaccination of HIV patients evidence based? J Clin Virol. 2001 Oct; 22(3):255-61

Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE; Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001 Mar 1;32:794-800.

Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold AL. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med. 2000 Sep 25;160(17):2633-8.

French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, Whitworth J, Gilks CF. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000 Jun 17; 355(9221):2106-11.

Fedson DS, Watson M. Pneumococcal vaccine and HIV-1 infection. Lancet 2000 Oct 7;356:1272.

French N, Gilks CF, Mujugira A, Fasching C, O'Brien J, and Janoff EN.. Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures. Aids 1998; 12(13): p. 1683-9.

Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis. 1996 Apr;173(4):857-62.

PPV23 and influenza

Toschke AM, Arenz S, von Kries R, Puppe W, Weigl JA, Höhle M, Heininger U. No temporal association between influenza outbreaks and invasive pneumococcal infections. Arch Dis Child. 2008 Mar;93(3):218-20.

McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006;19(3):571-82.

Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006; 6(5):303-12.

M, Gilmour R, Menzies R, et al. The association of respiratory viruses, temperature, and other climatic parameters with the incidence of invasive pneumococcal disease in Sydney, Australia. Clin Infect Dis 2006; 42: 211–15.

Talbot TR, Poehling KA, Hartert TV, Arbogast PG, Halasa NB, Edwards KM, Schaffner W, Craig AS, Griffin MR. Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med. 2005 Mar;118(3):285-91.

van der Sluijs KF, van Elden LJ, Nijhuis M, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004; 172: 7603–9.

Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 2004; 23: S87–97.

Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003; 21(16):1762-8.

Pons-Catalano C, Vallet C, Lorrot M, et al. Community acquired pneumonia and influenza in children. Arch Pediatr 2003; 10: 1056–60.

O'Brien KL, Walters MI, Sellman J, et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 2000; 30(5):784-9.

Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, Leinonen M, Kivela SL, Makela PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17(20-21): p. 2493-500.

Schwarzmann SW, Adler JL, Sullivan RJ, Jr., Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med 1971;127(6):1037-41.

Petersdorf RG, Fusco JJ, Harter DH, Albrink WS. Pulmonary infections complicating Asian influenza. AMA Arch Intern Med 1959;103(2):262-72.

Robertson L, Caley JP, Moore J. Importance of Staphylococcus aureus in pneumonia in the 1957 epidemic of influenza A. Lancet 1958; 2(7040):233-6.

Fry J. Influenza A (Asian) 1957: Clinical and Epidemiological Features in a General Practice. British Medical Journal 1958; 2:259-261.

Spooner LH, Scott LH, Heath EH. A bacteriologic study of the influenza epidemic at Camp Devens, Mass. JAMA 1919; 72:155-159.

Abrahams A, Hallows N, French H. A further investigation into influenza pneumococcal and influenza-streptococcal septicaemia: epidemic influenzal "pneumonia" of highly fatal type and its relation to "purulent bronchitits". Lancet 1919; 1:1-11.

Hall JN, Stone MC, Simpson JC. The epidemic of pneumonia following influenza at Camp Logan, Texas. JAMA 1918; 71:1986-87.

Nuzum JW, Pilot I, Stangl FH, Bonar BE. Pandemic influenza and pneumonia in a large civilian hospital. JAMA 1918; 71:1562-65.

Brem WV, Bolling GE, Casper EJ. Pandemic influenza and secondary pneumonia at Camp Fremont, Calif. JAMA 1918; 71:2138-44.

PPV23 and pregnancy

Quiambao BP, Nohynek HM, Käyhty H, Ollgren JP, Gozum LS, Gepanayao CP, et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007; 25:4470-7.

Shann F. Giving pneumococcal vaccine to mothers. Vaccine 2007; 25:6147.

Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, Lumbiganon P, DeSimone JA, Baxter J, Tolosa JE. Pneumococcal vaccination during pregnancy for preventing infant infection (Review). Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004903.

Gall SA. Maternal immunization to protect the mother and the neonate. Expert Rev. Vaccines 2005; 4:813-8.

Deubzer HE, Obara SK, Newman VO, Adegbola RA, Greenwood BM, Henderson DC. Colostrum obtained from women vaccinated with pneumococcal vaccine during pregnancy inhibits epithelial adhesion of Streptococcus pneumoniae. J Infect Dis 2004; 190:1758-61.

Lehmann D, Pomat WS, Combs B, Dyke T, Alpers MP. Maternal immunization with pneumococcal polysaccharide vaccine in the highlands of Papua New Guinea. Vaccine 2002 Mar 15;20:1837-45.

Lehmann D, Pomat WS, Riley ID, Alpers MP. Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. Vaccine 2003 Jul 28;21: 3446-50.

Munoz FM, Englund JA, Cheesman CC, Maccato ML, Pinell PM, Nahm MH, Mason EO, Kozinetz CA, Thompson RA, Glezen WP. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001 Dec 12;20:826-37.

O'Dempsey TJD, McArdle T, Ceesay SJ, Banya WAS, Demba E, Secka O, Leinonent M, Kgyhtyt H, Francist N, Greenwood BM. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 1996;14:962-70.

Shahid NS, Steinhoff MC, Hoque SS, Begum T, Thompson C, Siber GR. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet, 1995; 346(8985): p. 1252-7.

Immunological aspects; duration of protection and booster doses

O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007 Sep; 7(9):597-606.

Käyhty H, Nurkka A, Soininen A, Väkeväinen M. WHO Immunological Basis for Immunisation Series. Module x: Pneumococcal vaccines. 2008, draft.

Rose MA, Schubert R, Strnad N, Zielen S. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol 2005 Oct;12(10):1216-22.

Torling J, Hedlund J, Konradsen HB, et al. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22:96-103.

Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003 Apr;16:308-18.

Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:761-764.

Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999 Nov;67:5979-84.

Sankilampi U, Honkanen PO, Bloigu A, et al. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 176:1100-1104.

Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, Shamberger RC, Phillips NR, Goorin A, Ambrosino DM. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996 Jan;173(1):256-8.

Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995 ; 21:616-620.

Davidson M, Bulkow LR, Grabman J, et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994; 154:2209-2214.

Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 1993; 17:66-73.

Mufson MA, Hughey DF, Turner CE, et al. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991; 9:403-407.

Kaplan J, Sarnaik S, Schiffman G. Revaccination with polyvalent pneumococcal vaccine in children with sickle cell anemia. Am J Pediatr Hematol Oncol 1986; 8:80-82.

Carlson AJ, Davidson WL, McLean AA, et al. Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine. Proc Soc Exp Biol Med 1979;161:558-563.

Borgono JM, McLean AA, Vella PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978; 157:148-154..

Adverse events

Jackson LA, Nelson JC, Whitney CG, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006; 24:151-156.

Walker FJ, Singleton RJ, Bulkow LR, et al. Reactions after three or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 2005; 40:1730-1735.

Jackson LA, Neuzil KM, Whitney CG, et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2005; 23:3697-3703.

Lackner TE, G Hamilton R, J Hill J, et al. Pneumococcal polysaccharide revaccination: immunoglobulin g seroconversion, persistence, and safety in frail, chronically ill older subjects. J Am Geriatr Soc 2003; 51:240-245.

Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, Lezhava T, Williams WW.Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999 Jan 20; 281(3):243-8.

Rodriguez R, Dyer PD. Safety of pneumococcal revaccination. J Gen Intern Med 1995; 10:511-512.

Nelson K, Goldman JA, Perlino CA. Severe local reactions to pneumococcal vaccine. South Med J 1980; 73:264-265.

Economical studies

Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, KF-S, McEllistrem MC, RobertsMS. Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis. Vaccine 2008;11(Mar 10):1420-31.

Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, Wittrup-Jensen K, Loiseau C, Fedson DS. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007 Aug; 26(8):531-40.

Mangtani P, Roberts JA, Hall AJ, Cutts FT. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol 2005 Jun; 34(3):565-74.

Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 2004;19(4):365-75.

Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003 Jun 17; 138(12):960-8.

Pepper PV, Owens DK. Cost-effectiveness of the pneumococcal vaccine in healthy younger adults. Med Decis Making. 2002 Sep-Oct; 22(5 Suppl):S45-57.

Postma MJ, Heijnen ML, Jager JC.Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 2001;19(2):215-22.

Ament A, Fedson DS, Christie P. Pneumococcal vaccination and pneumonia: even a low level of clinical effectiveness is highly cost-effective. Clin Infect Dis 2001 Dec 15; 33(12):2078-9.

Hutton J, Iglesias C, Jefferson TO. Assessing the potential cost-effectiveness of pneumococcal vaccines: methodological issues and current evidence. Drugs Aging 1999; 15 (suppl 1): 31-36.

Fiore AE, Levine OS, Elliott JA, Facklam RR, Butler JC. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis 1999 Nov-Dec; 5(6):828-31.

Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, Plouffe JF,Cetron, MS, Butler JC. Cost effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9.

Policy issues

Use of pneumococcal polysaccharide vaccine for subjects over 65 years of age during and inter-pandemic period. Technical Report of the Scientific Panel on Vaccines and Immunization**, European Centre for Disease Prevention and Control (ECDC),** Stockholm, Sweden. Available at (http://www.ecdc.eu.int), 18 January 2007

Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule - United States, October 2006-September 2007. MMWR 2006; 55(40): p. Q1-Q4.

Levine OS, Cutts FT. Pneumococcal vaccination and public health. Lancet 2007 Apr 7; 369(9568):1144-5.

Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman KP, Madhi SA, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott JA, Sow S, Whitney CG, Cutts F. Pneumococcal vaccination in developing countries. Lancet 2006 Jun 10; 367(9526):1880-2. No abstract available.

Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Euro Surveill. 2005 Sep;10(9):174-8.

Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis. 2004 Jul; 4(7):445-55.

Prevention of Pneumococcal Disease - Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. Recommendations and Reports Series (RR) 1997; 46:No.RR-8.

Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.JAMA 1993; 270(15):1826-31.